Want to see IN:BALAXI full AI Analyst Report?
BALAXI Stock Chart & Stats
₹27.06
-₹2.28(-2.93%)
At close: 4:00 PM EST
₹27.06
-₹2.28(-2.93%)
Day’s Range― - ―
52-Week Range₹15.20 - ₹45.34
Previous CloseN/A
Volume27.88K
Average Volume (3M)49.53K
Market Cap
₹1.23B
Enterprise Value₹1.30K
Total Cash (Recent Filing)₹145.59M
Total Debt (Recent Filing)₹576.49M
Price to Earnings (P/E)49.5
Beta1.04
Next Earnings
Oct 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.7%
Share Statistics
EPS (TTM)0.26
Shares Outstanding55,207,500
10 Day Avg. Volume26,326
30 Day Avg. Volume49,535
Financial Highlights & Ratios
PEG Ratio-0.64
Price to Book (P/B)0.34
Price to Sales (P/S)0.31
P/FCF Ratio-1.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Moderate LeverageModerate leverage and an expanding equity base provide financial capacity to support operations and absorb volatility. With debt-to-equity near 0.23, the company is not currently dependent on heavy borrowing, although returns on that capital remain weak.
Gross MarginA gross margin of about 41.7% indicates the commercialized portfolio retains meaningful economics after product costs. If maintained, this cushion can help fund distribution, market execution, and operating investment even when revenue growth is uneven.
Commercialization FocusA commercialization-focused model lets Balaxi generate revenue from marketed medicines without relying on discovery-led drug development. Product breadth, market reach, and execution can support scalable participation in healthcare demand across selected markets.
Bears Say
Persistent Cash BurnNegative operating cash flow in FY2025 and FY2026, together with deeply negative free cash flow, shows that reported earnings are not converting into cash. Persistent cash consumption can raise funding needs and restrict reinvestment or working-capital flexibility over coming quarters.
Profitability CompressionNet margin fell to about 0.5% in FY2026 from 8.7% in FY2025, while operating profitability also weakened. This sharp compression leaves little earnings cushion against cost pressure and makes near-term profit generation less resilient despite a still-solid gross margin.
Uneven Revenue TrajectoryRevenue performance has become uneven: FY2026 declined 1.3% after 19.7% growth in FY2025, and the reported level remains below FY2023. Such a choppy top line can make planning, operating leverage, and sustained profitability harder to maintain.
Balaxi Pharmaceuticals Limited News
BALAXI FAQ
What was Balaxi Pharmaceuticals Limited’s price range in the past 12 months?
Balaxi Pharmaceuticals Limited lowest stock price was ₹15.20 and its highest was ₹45.34 in the past 12 months.
What is Balaxi Pharmaceuticals Limited’s market cap?
Balaxi Pharmaceuticals Limited’s market cap is ₹1.23B.
When is Balaxi Pharmaceuticals Limited’s upcoming earnings report date?
Balaxi Pharmaceuticals Limited’s upcoming earnings report date is Oct 30, 2026 which is in 27 days.
How were Balaxi Pharmaceuticals Limited’s earnings last quarter?
Balaxi Pharmaceuticals Limited released its earnings results on Aug 05, 2026. The company reported ₹0.235 earnings per share for the quarter.
Is Balaxi Pharmaceuticals Limited overvalued?
According to Wall Street analysts Balaxi Pharmaceuticals Limited’s price is currently Overvalued.
Does Balaxi Pharmaceuticals Limited pay dividends?
Balaxi Pharmaceuticals Limited pays a Notavailable dividend of ₹0.5 which represents an annual dividend yield of 0.7%. See more information on Balaxi Pharmaceuticals Limited dividends here
What is Balaxi Pharmaceuticals Limited’s EPS estimate?
Balaxi Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Balaxi Pharmaceuticals Limited have?
Balaxi Pharmaceuticals Limited has 55,207,500 shares outstanding.
What happened to Balaxi Pharmaceuticals Limited’s price movement after its last earnings report?
Balaxi Pharmaceuticals Limited reported an EPS of ₹0.235 in its last earnings report. Following the earnings report the stock price went up 0.583%.
Which hedge fund is a major shareholder of Balaxi Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:BALAXI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Balaxi Pharmaceuticals Limited
Balaxi Pharmaceuticals Limited, through its entity Balaxi Ventures Ltd., primarily operates as an international wholesale distributor specializing in pharmaceuticals, various food items, and hardware supplies. The company's corporate base is situated in Hyderabad, Telangana. Its extensive product range features pharmaceutical formulations, a variety of food products, and construction-related hardware. Notably, both its pharmaceutical and builders' hardware offerings are manufactured under contract at different plants located across India. Within its food segment, the firm markets a selection of food and biscuit products under the recognizable brand name YAP. Balaxi Global DMCC is among the key subsidiaries within the company's structure.
Technical Analysis
Alpa Laboratories Limited
―
Bal Pharma Limited
―
Par Drugs and Chemicals Limited
―
Natural Capsules Limited
―
Bilcare Ltd
―